Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Meningitis still affects more than 2.5 million people globally each year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Medicines, including insulin, to be available in 40 lower-income countries
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Subscribe To Our Newsletter & Stay Updated